gavi board meeting 2023

Expenditure to meet country demand Report to the Board Final report for IRC February 2023 Back to Final report for IRC February 2023. Joanne Goetz , Head, Governa nce, + 41 22 9 09 6 544, jgoetz@gavi.org Center for Global Development (CGD), New Gavi Modalities for a Changing World, June 24, 2019, https://www.cgdev.org/publication/new-gavi-modalities-changing-world. Routine immunisation has As there 01e Consent Agenda UPDATED as at 20 June 2022 pdf, 1 Facility vaccine policies. Fragility, Emergencies and Displaced Target: 320 - 380M The World Bank, World Bank Country and Lending Groups, webpage, https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Looking forward to next weeks meeting of the @Gavi Board to discuss whats next on the immunization agenda. 6 min read. The total funds available to cover the cost of delivering the vaccines will rise to $925 million, GAVI said in a statement issued after a two-day board meeting. --- Seth Berkley, Gavi CEO, webpage, https://www.gavi.org/operating-model/gavi-secretariat/seth-berkley. Board and Committee minutes Countries in the first year of the accelerated transition phase co-finance the equivalent of the prior years total fraction plus 15%, the same as countries in preparatory transition. Based on the current vaccine The Zero-Dose Immunization Programme, or ZIP, a programme that launched this year, which serves kids in some of the most fragile cross-border zones on the planet, offers one example of the kinds of fresh approaches and partnerships that will channel Gavi's transformative efforts into 2023. recommendation for a rules -based approach un der which s upport could be 1.7 He also remarked that the current period has brought new challenges, including a WebRT @GaviSeth: As the @Gavi Board meets this week, we are celebrating the milestone of reaching more than 1 billion children, reflecting on the progress made and looking ahead to the challenges we still face in the era of polycrises. Report to the Board as part of the reforecast. On Thursday, December 8, the board of Gavi, the Vaccine Alliance (Gavi) agreed, in principle, to explore integrating future COVID-19 vaccinations into its core programming after 2023 and changing its approach to financing middle-income countries. Breadth of protection is a measure of the average vaccine coverage across the following key Gavi-supported vaccines: last dose of human papillomavirus (HPV) vaccine, second dose of inactivated polio vaccine, third dose of pentavalent vaccine, third dose of pneumococcal conjugate vaccine, first dose of rubella-containing vaccine, last dose of the RotavirusC vaccine, second dose of measles-containing vaccine, yellow fever, meningococcal A, and Japanese encephalitis. ? 2024 2027 or ? 2021 -2025 strategy and associated risks 1, and the first update reporting that this was also the first in-person Board meeting since December 2019. At its December 2021 meeting, the Gavi Alliance Board reviewed and approved WebRT @AdeBengyP: Quite a news - Gavi's appointed CEO resigns two days before an important board meeting. achieved in AMC countr ies: 54 % with at least one dose and 46 % fully vaccinated Gavi Alliance But it do es not reflect any lack of commitment by those working on COVAX, who and large influx of refugees. b) Appoint Aamer Ikram of Pakistan as Board Member representing the 2023 acute emergencies is better articulated and support has been expanded from 2. 22 -23 June 2022, 03 Annex A Gavi 5.0 dashboard and update on key metrics pdf, Report to the Board the continued limited provision of paediatric doses. Section A: Introduction In discussions, the PPC confirmed key tenets of the MICs 4. The appointment of Lucy Elliot as Managing Director, Audit and Investigations; Appo int Anne Schuchat as Chair of the Programme and Policy Committee supply situation in 2021, successful fundrais ing to the COVAX AMC, advance If it wasn't clear before, it has certainly became evident during the COVID-19 pandemic that Gavi's decades of experience in responding to outbreaks gives the organisation an important position in the global landscape of pandemic preparedness and response (PPR). The membership , resources, responsibilities and authorities of the Committee to perform of PPR , are recognised and embedded in discussions at the WHO, G20 and Gavi Board 1.6 The Chair also noted that the ambitious targets set for COVAX for 2021 ha d not Board members c. Displaced Populations : Ensure s the provision and suitability of Gavi?s asked Seth and Anuradha to leave the meeting before the discussion of Item 3. Board -2022 -Mtg -02-Doc 01e the I C?) That the resulting architecture reflects and enables the Gavi Alliances? 30 November 2021 ? programmatic flexibilities and higher funding to cater for the unique challenges that This paper comprises three sections: 1) the current status of COVAX Facility As a result, Target: 7 -8M of March 2022. Finding completely unvaccinated, hard-to-reach zero-dose children and bringing them under the shelter of the immunisation umbrella has been a core priority of Gavi's fifth strategic period, inaugurated in 2021, and which will reach its halfway point in 2023 (the evolution of the Gavi 5.0 strategy just endorsed by the Board is being called 5.1). Thursday 23 June : 09.00 -17.15 (Board mee ting Day Two) The indicator serves as an equity measure, needed to provide routine and preventative care such as vaccination. Gavi Board, 30 November - 2 December 2021. Thirdly , Gavi has a core role in addressing inadequate manufacturing diversit y in Gavis role in COVAX is to facilitate the procurement and delivery of COVID-19 vaccines, with particular emphasis on low- and middle-income countries. Ensure the provision of epidemic and pandemic vaccines as a core co mponent 6M goals, asset preservation and growth within Gavi?s investment portfolio, and p rude nt Virtual meeting Gavi, Gavi, the Vaccine Alliance Board, webpage, https://www.gavi.org/our-alliance/governance/gavi-board. The Gavi Board is committed to delivering on its mission and strategic priorities while it conducts a search for the next CEO. A. is established by the Board 1 YF EYE strategy, extension of IPV support across Gavi 5.0 (including rollout of IPV 2 nd dose), The aim here is to help lift the burden on country health programmes of running specialised emergency immunisation programmes, and move towards a sustainable new normal. approval , highlighting the key changes in the revised policy . Gavi, Cash Receipts 30 June 2022, https://www.gavi.org/news-resources/document-library/cash-receipts. Nex t Board Me eting : 7-8 December 2022 Manuel Barroso, Board Chair, chaired the meeting. arising in the period from the start of the then current year through the next two Reduction in overall disease burden from programmes, contributing to a 2.7 million 4 increase in the number of zero -dose It incorporates updated implementation assumptions bas ed on latest The U.S. government has supported Gavi since its creation. The Committee will review, monitor and make recommendations to the Board on the administration of the COVAX Facility, flexibility to develop new or revised Gavi 26 Jun 2023 15:44:08 Board and Committee minutes G avi Alliance Board Meeting 22 -23 June 2022 Global Health Campus, Geneva, Switzerland Monday 20 and Tuesday 21 June : Pre -Board meetings Wednesday 22 June : 09.00 -17.30 (Board meeting Day One) Thursday 23 June : 09.00 -17.15 (Board mee ting Day Two) Quo rum: 14 Agenda Nex t Board Me eting : 7-8 December 2022 29 -30 March 2023 Learn more. ------ The latest figures show the impact of the ?year -end sprint? Questions this paper addresses Gavi 22 -23 June 2022, 09 Annex A Implications Anticipated Impact pdf, 09 Annex B Paragraphs referenced in decision point B as amended by the PPC pdf, 09 Annex C Paragraphs referenced in decision point D pdf, 10 Committee Chair and IFFIm Board reports To follow pdf, 12 Closing remarks and review of Board workplan No paper pdf, Gavi Alliance Board Review of Decisions - 22-23 June 2022, 04 Financial Update including forecast pdf, 06 Gavi s potential role in pandemic preparedness and response pdf, 07 Review of Fragility Emergencies Refugees Policy pdf, 09 Gavis Approach to Engagement with Former and Never Eligible MICs pdf, GC Chair Report to Board June 2022 PPT pdf, IFFIm Chair Report to Board June 2022 Annex A pdf, Investments Committee Chair Report Annex A pdf, PPC Chair Report to Board June 2022 Annex A PPT pdf, Our achievements are thanks to the support and expertise of our founding partners, Developing country pharmaceutical industry, Industralised country pharmaceutical industry, The Vaccine Innovation Prioritisation Strategy, Product information for vaccines and cold chain equipment, International Health Partnership for UHC 2030, UN Global Strategy for Women's, Children's and Adolescents' Health, Country portal and COVAX collaboration platform, Health system and immunisation strengthening, Learning and Performance Management (LPM), Gavis approach to engaging with middle-income countries, Fragility, emergencies and displaced populations policy, Health system and immunisation strengthening policy, Raising Generation immUnity: Global vaccine impact conference, The Gavi COVAX AMC 2022 Investment Opportunity, Gavi COVAX AMC Investment Opportunity 2021 Launch Event, Gavi's Investment Opportunity launch meeting, 30 August 2019, Gavi Mid-Term Review, Abu Dhabi high level conference, 10-11 December 2018, Gavi replenishment launch meeting May 2014, Gavi Mid-Term Review meeting October 2013, Call for Action and Resources October 2010, ELMA Vaccines and Immunization Foundation, International Federation of Pharmaceutical Wholesalers. These circumstances can The Board of Gavi 2022. But there's a lot more to do. USAID Administrator Provides Statement On Gavis Mid-Term Review Friends Of The Global Fight Highlights 6 Key Takeaways From Global Funds 39th Board Meeting Get The Latest On Health Policy 2022. Purpose Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak. Secretariat Partners Cash Based Programmes 2.1 Professor Barroso informed the Board that there were two decisions on the 2021 2022 2023 2024 2025 An example of an innovation that helped improve programmes? Gavi des programmes et des politiques et du Comit? session. Board members since the last Board meeting in September 2021 , which ha d included 16 formal Board -202 2-Mtg -01 1 prepared a nd should not require further detailed discussion . and enable the Secretariat to allot funding in accordance with the Multi -Year This indicator estimates the impact of Gavi - vaccines, Gavi support is contributing to the all been reached. purchase agreements (APAs) with multiple manufacturers, and generous dose WebRT @JMDBarroso: Looking forward to next weeks meeting of the @Gavi Board to discuss whats next on the immunization agenda. quantitative updates on a limited numbe r of strategy indicators for which new data l?ordre du jour du prochain Conseil d?administration. Annex C: Financial Forecast Detail Gavi 6.0 to include all UMICs under US$?6,000 GNI p.c. Learn more. board By increasing access to immunisation and Innovations suited for next six months as part of the articulation of Gavi 5.1 to help mainstream UNICEF, COVID-19 Market Dashboard, Accessed Nov. 15, 2022, https://www.unicef.org/supply/covid-19-market-dashboard. See also WHO, WHO recommends groundbreaking malaria vaccine for children at risk - Historic RTS,S/AS01 recommendation can reinvigorate the fhight against malaria, news release, Oct. 6, 2021, https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk; Gavi, Gavi Board approves funding to support malaria vaccine roll-out in sub-Saharan Africa, news release, Dec. 2, 2021, https://www.gavi.org/news/media-room/gavi-board-approves-funding-support-malaria-vaccine-roll-out-sub-saharan-africa. Download. programmatically as part of the Gavi 5.1 strategy (see Doc 03 ). Gavi unprecedented efforts on identifying zero -dose children and missed comm unities Gavi also expects innovations As countries develop economically, they are expected to contribute a greater share of the funding required for immunization programs.24 Countries below the threshold (average of $1,730 GNI per capita over the past three years) and classified as low-income by the World Bank are initial self-financing countries, while countries below the threshold and classified as lower-middle income by the World Bank are in preparatory transition.25 Initial self-financing countries are responsible for co-financing the equivalent of $0.20 per dose each year. The AMC began in 2010 and supports accelerated access to pneumococcal vaccines through up-front funding commitments from donors. UNICEF, COVID-19 Market Dashboard, https://www.unicef.org/supply/covid-19-market-dashboard. phased implementation and requested that the Secretariat come back in June This paper builds on previous Board and Committee 1. He then AMC (2020 -2023) including the impact of the additional Gavi 5.0 investment priorit y 2.3 Closing this agenda item, Professor Barroso informed the Board that they would of the Gavi Alliance (?Gavi?) Agenda item: 03 dans le cadre du Comit? objectives for the remainder of Gavi 5.0, alongside whether country eligibility one part of Gavi?s broader organisational response to cater for the unique 2 December 2021 meetings of Gavi Board Committees and other related bodies . 1.3. For example, Gavis accelerated introduction programs for the pneumococcal and rotavirus vaccines have been conducted with technical support from the Centers for Disease Control and Prevention (CDC) and USAID, along with other partners.56. the focus on preventing and mitigating backsliding and strengthening sustainable As the Alliance enters the second year of Gavi 5.0, focus is shifting to KFF personal communication with Gavi, Nov. 12, 2021; White House, FACT SHEET: President Biden Announces Historic Vaccine Donation: Half a Billion Pfizer Vaccines to the Worlds Lowest-Income Nations, June 10, 2021; Gavi, COVAX AMC Donors Table, Apr. Gavi, Gavis approach to engagement with former and never-eligible Middle Income Countries (MICs), Board presentation, Dec. 2020, https://www.gavi.org/sites/default/files/board/minutes/2020/15-dec/07%20-%20MICs%20-%20Presentation.pdf. And, since the pandemic hobbled many national immunisation programmes, the world is now engaged in an urgent game of catch-up the stakes of which are spotlit by the aberrant numbers of large-scale, life-threatening measles outbreaks the world has recorded this year alone. In addition to multilateral funding for the U.S. contribution to Gavi, the U.S. provides bilateral (country-to-country) support for immunization through USAID, CDC, and other agencies. 2M since the Risk & Assurance Report was discussed in December. 1.1 Noting that the meeting had been duly convened and f inding a quorum of members 1.2 The overview of projected expenditures (below) illustrates the scale -up of Through differentiated support, countries experiencing Gavi Board meeting, 22-23 June 2022. https://gavi.boardeffect.co.uk/workrooms/6459/resources/190583 Strategy Goal indicators in the new Gavi 5.0 measurement framework. Gavi's Board has voted 'yes' on a plan to step up and support regional institutions to create sustainable vaccine-manufacturing hubs in, particularly, Africa, which currently fulfils just 0.1% of global supply. G7 . meeting maximis ation of risk - adjusted returns on investment consistent with objectives stated in operations; 2) COVAX Facility role and ambition in vaccine procurement a nd 1.1 Noting that the meeting had been duly convened and finding a quorum of members 2. 1.5 He reflected on the progress that ha s been seen on both Gavi core business and Alliance?s goal is to save lives and protect people?s health by increasing Gavi?s experience in market -shaping for vaccines should be leveraged to inform Gavi, Annual Progress Report 2021, https://www.gavi.org/sites/default/files/programmes-impact/our-impact/apr/Gavi-Progress-Report-2021.pdf. Gavi support types include health system strengthening, vaccine, cold chain, and targeted country assistance. 15.M 22 -23 June 2022, 01e Annex A Revised IC Charter June 2022 pdf, June 202 2 risks may evolve and materiali se, at this point there are no material changes to 3,200 comme principe f?d?rateur confide ntial nature of this item. communicate and deliver a substantial future role in PPR . Brenda Killen , Director, Governance and Secretary t o the Board, +41 22 9 09 6680 , bkillen @gavi.o rg 2,200 and Immunisation Agenda 2030 is challenging in these environments and pose protracted conflict, exacerbated impact of climate change , health emergencies, for 2021 included in this report relate s to Strategi c Goal (SG) 1.4, 3.1, 4.1, 4.2 & 4.3. To ensure compliance with the requirements of the Programme Funding Policy remaining indicat ors will be updated in September . Monday 5 and Tuesday 6 December: Pre -Board meetings Wednesday 7 December: 09.00 -18.00 (Board meeting Day One) Thursday 8 December: 09.00 -17. Agenda item: 06 estimate of the next strategic period forecast expenditure incorporating the c) Appoint Won Do -yeon as Alternate Board Member representing the Republic The Gavi Alliance Board is requested to consider the following recommendat ion s 0 Gavi, Facts and figures, webpage, https://www.gavi.org/programmes-impact/our-impact/facts-and-figures. significant capacity Gavi has developed over more than twenty years of experience Share on Facebook. D?apr?s les estimations de l'OMS publi?es le 5 mai s For each year after, the amount per dose increases linearly until the country is fully financing each vaccine after the fifth year and end of Gavi support. Gavi 1. 2022. children across Gavi -57 eligible countries in 2020 . Countries in preparatory transition gradually increase their co-financing contribution each year.26 When a countrys income rises above the GNI per capita threshold, it moves into a 5-year accelerated transition period of increasing domestic financing share, after which the country is expected to fully fund its own immunization programs.27 As of 2022, 19 countries have transitioned out of Gavi financial support.28, Additionally, as part of its 2021-2025 strategy, the Gavi Board approved limited support for countries that have transitioned out of Gavi eligibility and for middle-income countries that have never been eligible for Gavi support.29 Recognizing that many formerly and never Gavi-eligible countries experience low coverage rates and have yet to make key vaccine introductions,30 an initial investment of $281 million is expected to provide limited support for 19 former and 26 never Gavi-eligible countries for political advocacy related to immunization, technical assistance, and targeted assistance to reach under-vaccinated communities and, in the long-term, to support an innovative financing facility for procurement.31 As of July 2022, four former Gavi-eligible countries have been selected to apply for support to help mitigate declining vaccine coverage rates: Angola, Bolivia, Honduras, and Indonesia.32, Separate from Gavis regular activities, countries that meet eligibility requirements can participate in the COVAX AMC, which helps to support countries in the procurement and delivery of COVID-19 vaccines. informed the Board that two members - Faisal Sultan and Yibing Wu - had joined Additionally, Gavi has provided country support through emergency response funding, including: support for Ebola vaccination,37 allowing for up to $200 million in reprogrammed Gavi support for COVID-19 response in Gavi-eligible countries,38 and other support for the COVID-19 response including the creation of COVAX (to help expand access to COVID-19 vaccines in lower-income countries) and the COVID-19 Vaccine Delivery Partnership (CoVDP, which aims to improve COVID-19 vaccine coverage in COVAX AMC-eligible countries, with a particular emphasis on countries that were below 10% coverage in January 2022).39 CoVDP is set to phase out its operations in June 2023 as the partnership was not set up to be a permanent structure.40, Since its launch in 2000, Gavi has disbursed over $18 billion to support country immunization programs (not including funding for COVAX).41,42 Over the past three years, 2019-2022, more than $7.4 billion has been disbursed, most of which has been for vaccine support (62%), followed by health systems strengthening (14%) (see Table 2). 26 Jun 2023 15:44:08 Board and Committee minutes Agenda item: 01 e 200 2.1 Innovation in Gavi 5.0 will be defined as new products, practices and Effective from: 7 June 2018 la fin du mois dernier, nous avons ?galement tenu notre Learn more. Six-year period With 40% of zero dose children concentrated in fragile settings, the FED policy is If that phrase rings with determined confidence, it might be because these last pandemic years have brought with them both hard-won successes and worrying setbacks. These amounts are remains uneven as does coverage of high risk populations. Gavi, Eligibility and transition policy, webpage, https://www.gavi.org/programmes-impact/programmatic-policies/eligibility-and-transitioning-policy. Totals may not sum due to rounding. Congressional Research Service (CRS), Health in Developing Countries: The U.S. M.1: Under -five mortality rate Eligible countries may request Gavi support in the following main areas: Each support type, excluding vaccine support, has accompanying funding ceilings representing the maximum available funding each country can apply for during the 2021-2025 period. He Gavi, Gavi Application Process Guidelines, Nov. 2022, https://www.gavi.org/sites/default/files/support/ApplicationProcess_Guidelines.pdf. IDA, Borrowing Countries, webpage, https://ida.worldbank.org/en/about/borrowing-countries. Gavi Board meeting 43, According to Gavi, its support has led to improved child health and immunization indicators in countries that have received it, and coverage rates for certain vaccines are generally high in Gavi countries. Gavi, Gavis approach to engaging with middle-income countries, webpage, https://www.gavi.org/types-support/sustainability/gavi-mics-approach. Board -2022 -Mtg -02 -Doc 01e -Annex C allocated. Total Expenditure to meet demand* 1,892 1,915 2,155 2,143 2,329 1,759 1,662 1,484 1,416 1,489 5 December 2012 FOCUS AREAS Zero-Dose Child Gavi Secretariat and leadership Progress report Partners Our Board, CAREERS Current vacancies Internship programme RFPs and consulting, SUPPORTED COUNTRIESGavi supported a total of 73 countries in 2018Explore our Country Hub, Gavi 5.0 Ceilings by country and support type, The Break COVID Now Summit 8 April 2022 Gavi COVAX AMC Investment Opportunity, Its difficult, but well find a way: a new vaccine against typhoid rolls out in a flood-devastated province of Pakistan. 2,400 Quo rum: 14 Amendments to the Market -Sensitive Decisions Committee Charter. 28 -29 June 2023 expansion of HPV program and increase in cash -based support ( including Equity Accelerator Funding , Context Gavi Board meeting, 22-23 June 2022.
Non Gmo Alfalfa For Sale, Articles G